product name Zalcitabine
Description: Zalcitabine (also known as NSC 606170, Ro 24-2027/000, and 2′,3′-Dideoxycytidine) is a nucleoside analog HIV reverse transcriptase inhibitor (NARTI). is an antiviral pyrimidine nucleoside analogue effective against HIV replication. 2′,3′-Dideoxycytidine, when activated to its triphosphate, is incorporated into DNA by HIV-1 RT (HIV-1 reverse transcriptase), causing DNA chain termination and viral replication.
References: Am J Med. 1990 May 21;88(5B):2S-7S; Acta Oncol. 1997;36(2):199-205.
211.22
Formula
C9H13N3O3
CAS No.
7481-89-2
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 42 mg/mL (198.8 mM)
Water: 42 mg/mL (198.8 mM)
Ethanol: <1 mg/mL
Solubility (In vivo)
Synonyms
NSC 606170, Ro 24-2027/000
other peoduct :
| In Vitro |
In vitro activity: It is phosphorylated in T cells and other HIV target cells into its active triphosphate form, ddCTP. This active metabolite works as a substrate for HIV reverse transcriptase, and also by incorporation into the viral DNA, hence terminating the chain elongation due to the missing hydroxyl group. Since zalcitabine is a reverse transcriptase inhibitor it possesses activity only against retroviruses Kinase Assay: Cell Assay: Two human cell lines, WiDr (colon) and MCF-7 (breast) were exposed to ddC at 10 microM concentration for various lengths of time (18, 24, 48 and 72 h). On the WiDr cell line the dual effect of concentration and duration of exposure prior to irradiation was investigated. For MCF-7, ddC induced a significant modification of the dose response only with 24 and 48 h preincubation. |
|---|---|
| In Vivo | |
| Animal model | |
| Formulation & Dosage | |
| References | Am J Med. 1990 May 21;88(5B):2S-7S; Acta Oncol. 1997;36(2):199-205. |
